EGFR and non-small cell lung carcinoma: We applied this model to screening data derived from a screen of a panel of genetically and phenotypically characterized NSCLC cell lines and determined global genetic settings in which synergy of the irreversible EGFR/ERBB2 inhibitor BIBW-2992 and a dual PI3K/mTOR inhibitor PI-103 is most pronounced.